TG Therapeutics Inc (TGTX)

Fixed asset turnover

		Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019
Revenue (ttm)	US$ in thousands	262,359	340,582	280,254	222,343	180,883	18,875	6,331	2,784	5,025	6,961	7,912	6,689	4,406	2,414	907	152	152	152	152	152
Property, plant and equipment	US$ in thousands	—	—	66	95	133	206	237	307	376	447	526	600	600	597	488	481	378	331	320	282
Fixed asset turnover		—	—	4,246.27	2,340.45	1,360.02	91.63	26.71	9.07	13.36	15.57	15.04	11.15	7.34	4.04	1.86	0.32	0.40	0.46	0.48	0.54

September 30, 2024 calculation

Fixed asset turnover = Revenue (ttm) ÷ Property, plant and equipment
= $262,359K ÷ $—K
= —

Fixed asset turnover is a financial ratio that measures a company's ability to generate revenue from its fixed assets. It indicates how efficiently a company is using its fixed assets to generate sales.

The fixed asset turnover for TG Therapeutics Inc has fluctuated significantly over the periods provided. It reached its peak in the most recent quarter, September 30, 2024, at 4,246.27, implying that the company generated $4,246.27 in revenue for each dollar invested in fixed assets during that period. This represents a substantial improvement in asset utilization compared to previous quarters.

Prior to the significant increase seen on September 30, 2024, the fixed asset turnover had been relatively low, with values ranging from 0.32 to 15.57 over the past few quarters. The ratios indicating asset turnover below 1 suggest that the company was not efficiently using its fixed assets to generate revenue during these periods.

The sharp increase in fixed asset turnover in the most recent quarter could suggest improved operational efficiency and better utilization of fixed assets to drive revenue generation. This increase may be due to factors such as increased production levels, better asset management, or higher sales volumes.

Overall, the trend in fixed asset turnover for TG Therapeutics Inc indicates variability in how effectively the company is utilizing its fixed assets to generate revenue, with the most recent quarter showing a significant improvement in asset efficiency. Continued monitoring of this ratio will be important to assess the company's ongoing operational performance and efficiency in utilizing its fixed assets.